French study of fat in the liver and related health outcomes
Part of Digestive system clinical trials.
This study follows adults with nonalcohol-related fatty liver disease (NAFLD) to better understand the condition and what factors affect it. It may help researchers learn which patients are most at risk and how care can be improved in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have a confirmed diagnosis of NAFLD (fatty liver not caused by alcohol)
- Be covered by French social security
- Sign a written informed consent form
- Avoid heavy alcohol use (more than 21 units/week for men or 14 for women in the last 6 months), or a long history of heavy alcohol use
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information about metabolic and unexplained (cryptogenic) liver disease and looks at “omics” tests, which are lab tests that measure patterns in blood or tissue to learn what drives the disease. It may help researchers better understand fatty liver and related serious complications, like liver scarring and liver cancer.
This study looks at people with fatty liver disease and common health issues like obesity, diabetes, high blood pressure, or abnormal cholesterol. It may help researchers understand how liver fat and heart/metabolism problems relate and how they affect health over time.
This registry collects health and lifestyle information from adults with suspected or confirmed fatty liver (NAFLD) to help researchers better understand the condition. You may be asked about diet, exercise, alcohol intake, and some liver-related tests.
This study collects health information and samples from people with non-alcoholic fatty liver disease to better understand the condition. It may help researchers find new ways to diagnose or treat this liver problem.
This study tests a way to find liver scarring (fibrosis) early in people who have risk factors like being overweight, having type 2 diabetes, or drinking alcohol heavily. Early detection may help prevent serious liver damage.
This study takes small samples of liver tissue to grow 3D 'mini livers' (organoids) in the lab. Researchers want to learn how non-alcoholic steatohepatitis (NASH), a serious fatty liver condition, starts and progresses, which could lead to better treatments.
Hear when a new NAFLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.